Plesiomonas shigelloides is a gram-negative rod belonging to the family Vibrionaceae that has recently been implicated as a cause of sporadic and epidemic diarrhea in immunocompetent hosts (1, 2, 4, 9) and severe extraintestinal disease in immunocompromised individuals (3) . Antimicrobial therapy appears essential for successful outcome with extraintestinal disease (3) , and recent studies suggest that antibiotics may shorten the often prolonged clinical course of intestinal disease (4, 5, 8) .
Previously published studies of P. shigelloides susceptibility testing have often involved small numbers of isolates from a variety of sources and strains originating from diverse geographic locations (1, 7, 10). Because of this we undertook antimicrobial susceptibility testing of fecal isolates of P. shigelloides from symptomatic patients in two institutions from a single geographic location.
Fecal isolates were recovered and identified at the Provincial Health Laboratory or the Metropolitan Clinical Laboratories from a symptomatic outpatient population as previously described (4) . MICs of 24 antimicrobial agents were determined for 72 isolates by a standard agar dilution technique with Mueller-Hinton agar (6) . Approximately 5 x 105 CFU of each isolate were inoculated onto freshly prepared media containing serial dilutions of different antimicrobial agents with a Steers multipoint replicator (Cathra International Inc., St. Paul, Minn.). Current National Committee for Clinical Laboratory Standards guidelines (M7-A-S2) for MIC interpretive standards were followed (Table 1) . Although the breakpoints used in this study may be useful in interpreting in vitro susceptibility of P. shigelloides in cases of extraintestinal infection (e.g., bacteremia), it should be noted that they are of limited value in cases of intestinal infection alone.
P. shigelloides has been previously shown to cause meningitis and sepsis in immunosuppressed patients and rarely in immunocompetent individuals as well (3). Since cephalosporins are frequently chosen for empiric treatment of gramnegative sepsis and meningitis, we tested isolates against various cephalosporins to determine the relative in vitro activity of each and compare them with aminoglycosides that were previously shown to be active in vitro (7) . Similar to other published reports (7, 10) , cefotaxime, ceftazidime, and ceftriaxone had good in vitro activity, and all isolates were susceptible to these agents (Table 1) . In addition, all * Corresponding author.
tested narrow-and extended-spectrum cephalosporins were active in vitro. The aminoglycosides, however, were not uniformly active; 36% of isolates were susceptible to tobramycin (MIC for 90% of isolates [MIC9], 6 ,ug/ml), 57% were susceptible to gentamicin (MIC90, 6 ,ug/ml), and 54% were susceptible to amikacin (MICg, 32 ,ug/ml). Netilmicin was the only aminoglycoside tested to which all isolates were susceptible (MIC90, 4 jxg/ml). These in vitro studies suggest that, with the exception of netilmicin, aminoglycosides may not be ideal empiric agents for the treatment of extraintestinal infection with P. shigelloides.
We have previously demonstrated that P. shigelloides could result in both locally acquired and traveler's diarrhea and that the institution of an appropriate antimicrobial agent resulted in a significantly shorter clinical course (4). For these reasons, oral agents potentially useful in the treatment of locally acquired and traveler's diarrhea were also examined for in vitro activity against Plesiomonas isolates (Table  1) . Norfloxacin, ciprofloxacin, and trimethoprim demonstrated the best in vitro activity. In contrast to another study (7) , all tested isolates were susceptible to trimethoprim. The reason for this disparity is not clear but could represent regional differences in the strains studied. Twenty-six percent of strains were resistant to tetracycline, and another 6% were intermediate. Ampicillin and the other tested penicillins were relatively inactive against P. shigelloides (MIC90, .128).
In summary, oral agents commonly used to treat bacterial diarrhea, particularly trimethoprim or cotrimoxazole and more recently norfloxacin, and ciprofloxacin have good in vitro activity against fecal isolates of P. shigelloides and may be useful in cases of intestinal infection where treatment is deemed necessary. Tetracycline might be considered for therapy if the isolate is known to be susceptible, but ampicillin is unlikely to show activity against any strain. Norfloxacin has excellent in vitro activity against P. shigelloides, similar to that seen against other bowel pathogens (11); because of its high levels in the gut, it may be more effective than standard agents against P. shigelloides intestinal infection. However, further studies are needed in this area. For parenteral treatment of severe extraintestinal infections, netilmicin and the cephalosporins have good in vitro activity. Penicillins cannot be recommended based on in vitro susceptibility testing.
ANTIMICROB. AGENTS CHEMOTHER. 
